ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Following the Company‘s press release published earlier today, the Q2 Consolidated Financial Statements and the MD&A, which have now been filed with the SEC on form 6-K, are attached.
Attachments
ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Following the Company‘s press release published earlier today, the Q2 Consolidated Financial Statements and the MD&A, which have now been filed with the SEC on form 6-K, are attached.
Attachments
FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program...
Read MoreFDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program...
Read More